Mkhobongo B, Chandran R, Abrahamse H. The role of melanoma cell-derived exosomes (MTEX) and photodynamic therapy (PDT) within a tumor microenvironment. Int J Mol Sci. 2021;22(18):9726.

Article  CAS  PubMed  Google Scholar 

Surman M, Stępień E, Przybyło M. Melanoma-derived extracellular vesicles: focus on their proteome. Proteomes. 2019;7(2):21.

Article  CAS  PubMed  Google Scholar 

Arnold M, Singh D, Laversanne M, Vignat J, Vaccarella S, Meheus F, et al. Global burden of cutaneous melanoma in 2020 and projections to 2040. JAMA Dermatology. 2022;158(5):495–503.

Article  PubMed  Google Scholar 

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin. 2021;71(3):209–49.

Article  Google Scholar 

Boussios S, Rassy E, Samartzis E, Moschetta M, Sheriff M, Pérez-Fidalgo JA, et al. Melanoma of unknown primary: new perspectives for an old story. Crit Rev Oncol/Hematol. 2021;158:103208.

Article  PubMed  Google Scholar 

Zbytek B, Carlson JA, Granese J, Ross J, Mihm M, Slominski A. Current concepts of metastasis in melanoma. Expert Rev Dermatology. 2008;3(5):569–85.

Article  CAS  PubMed  Google Scholar 

Nguyen K, Hignett E, Khachemoune A. Current and emerging treatment options for metastatic melanoma: a focused review. Dermatol Online J. 2020;26(7).

He G, Li Y, Zeng Y, Zhang Y, Jiang Q, Zhang Q, et al. Advancements in melanoma immunotherapy: the emergence of Extracellular Vesicle vaccines. Cell Death Discovery. 2024;10(1):374.

Article  CAS  PubMed  Google Scholar 

Korn EL, Liu P-Y, Lee SJ, Chapman J-AW, Niedzwiecki D, Suman VJ, et al. Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol. 2008;26(4):527–34.

Article  PubMed  Google Scholar 

Bedikian AY, Millward M, Pehamberger H, Conry R, Gore M, Trefzer U, et al. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol. 2006;24(29):4738–45.

Article  CAS  PubMed  Google Scholar 

Jenkins RW, Fisher DE. Treatment of advanced melanoma in 2020 and beyond. J Invest Dermatology. 2021;141(1):23–31.

Article  CAS  Google Scholar 

Xu Z, Zeng S, Gong Z, Yan Y. Exosome-based immunotherapy: a promising approach for cancer treatment. Mol Cancer. 2020;19:1–16.

Article  Google Scholar 

Sharma V, Mukhopadhyay CD. Exosome as drug delivery system: current advancements. Extracell Vesicle. 2024;3:100032.

Article  Google Scholar 

Mason R, Au L, Ingles Garces A, Larkin J. Current and emerging systemic therapies for cutaneous metastatic melanoma. Expert Opin Pharmacother. 2019;20(9):1135–52.

Article  PubMed  Google Scholar 

Knight A, Karapetyan L, Kirkwood JM. Immunotherapy in melanoma: recent advances and future directions. Cancers. 2023;15(4):1106.

Article  CAS  PubMed  Google Scholar 

Peggs KS, Quezada SA, Chambers CA, Korman AJ, Allison JP. Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodies. J Exp Med. 2009;206(8):1717–25.

Article  CAS  PubMed  Google Scholar 

Lang B, Peveling-Oberhag A, Faidt D, Hötker A, Weyer-Elberich V, Grabbe S, et al. Long-term survival with modern therapeutic agents against metastatic melanoma—vemurafenib and ipilimumab in a daily life setting. Med Oncol. 2018;35:1–12.

Article  CAS  Google Scholar 

Drysdale E, Peng Y, Nguyen P, Baetz T, Hanna TP. A population-based study of the treatment effect of first-line ipilimumab for metastatic or unresectable melanoma. Melanoma Res. 2019;29(6):635–42.

Article  PubMed  Google Scholar 

Chen DS, Irving BA, Hodi FS. Molecular pathways: next-generation immunotherapy—inhibiting programmed death-ligand 1 and programmed death-1. Clin Cancer Res. 2012;18(24):6580–7.

Article  CAS  PubMed  Google Scholar 

Boussiotis VA. Molecular and biochemical aspects of the PD-1 checkpoint pathway. N Engl J Med. 2016;375(18):1767–78.

Article  CAS  PubMed  Google Scholar 

Robert C, Ribas A, Schachter J, Arance A, Grob J-J, Mortier L, et al. Pembrolizumab versus Ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. Lancet Oncol. 2019;20(9):1239–51.

Article  CAS  PubMed  Google Scholar 

Robert C, Long GV, Brady B, Dutriaux C, Di Giacomo AM, Mortier L, et al. Five-year outcomes with nivolumab in patients with wild-type BRAF advanced melanoma. J Clin Oncol. 2020;38(33):3937.

Article  CAS  PubMed  Google Scholar 

Redman JM, Gibney GT, Atkins MB. Advances in immunotherapy for melanoma. BMC Med. 2016;14(1):20.

Article  PubMed  Google Scholar 

Andtbacka RH, Kaufman HL, Collichio F, Amatruda T, Senzer N, Chesney J, et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol. 2015;33(25):2780–8.

Article  CAS  PubMed  Google Scholar 

Qin S, Xu L, Yi M, Yu S, Wu K, Luo S. Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4. Mol Cancer. 2019;18:1–14.

Article  CAS  Google Scholar 

Maruhashi T, Sugiura D, Okazaki I-m, Okazaki T. LAG-3: from molecular functions to clinical applications. J Immunother Cancer. 2020;8(2).

Tawbi HA, Schadendorf D, Lipson EJ, Ascierto PA, Matamala L, Castillo Gutiérrez E, et al. Relatlimab and Nivolumab versus Nivolumab in untreated advanced melanoma. N Engl J Med. 2022;386(1):24–34.

Article  CAS  PubMed  Google Scholar 

Renato Filho S, Oliveira DA, Nisimoto MM, Marti LC. A review for Advanced Cutaneous Melanoma therapies and their mechanisms, from immunotherapies to Lysine Histone Methyl Transferase inhibitors. 2023.

Lopes J, Rodrigues CM, Gaspar MM, Reis CP. Melanoma Management: from epidemiology to treatment and latest advances. Cancers. 2022;14(19):4652.

Article  CAS  PubMed  Google Scholar 

Ihle MA, Fassunke J, König K, Grünewald I, Schlaak M, Kreuzberg N, et al. Comparison of high resolution melting analysis, pyrosequencing, next generation sequencing and immunohistochemistry to conventional Sanger sequencing for the detection of p. V600E and non-p. V600E BRAFmutations. BMC Cancer. 2014;14(1):1–13.

Article  Google Scholar 

Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med. 2012;367(2):107–14.

Article  CAS  PubMed  Google Scholar 

Ernst M, Giubellino A. The current state of treatment and future directions in cutaneous malignant melanoma. Biomedicines. 2022;10(4):822.

Article  CAS  PubMed  Google Scholar 

Long GV, Stroyakovskiy D, Gogas H, Levchenko E, De Braud F, Larkin J, et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet. 2015;386(9992):444–51.

Article  CAS  PubMed  Google Scholar 

Dummer R, Ascierto PA, Gogas HJ, Arance A, Mandala M, Liszkay G, et al. Encorafenib plus Binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2018;19(5):603–15.

Article  CAS  PubMed  Google Scholar 

Ascierto PA, Dummer R, Gogas HJ, Flaherty KT, Arance A, Mandala M, et al. Update on tolerability and overall survival in COLUMBUS: Landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600–mutant melanoma. Eur J Cancer. 2020;126:33–44.

Article  CAS  PubMed  Google Scholar 

Li C, Kuai L, Cui R, Miao X. Melanogenesis and the targeted therapy of Melanoma. Biomolecules. 2022;12(12):1874.